SUMMARY
Novel antiangiogenic strategies with complementary mechanisms are needed to maximize efficacy and minimize resistance to current angiogenesis inhibitors. We explored the therapeutic potential and mechanisms of aPlGF, an antibody against placental growth factor (PlGF), a VEGF homolog, which regulates the angiogenic switch in disease, but not in health. aPlGF inhibited growth and metastasis of various tumors, including those resistant to VEGF(R) inhibitors (VEGF R Is), and enhanced the efficacy of chemotherapy and VEGF R Is. aPlGF inhibited angiogenesis, lymphangiogenesis, and tumor cell motility. Distinct from VEGF R Is, aPlGF prevented infiltration of angiogenic macrophages and severe tumor hypoxia, and thus, did not switch on the angiogenic rescue program responsible for resistance to VEGF R Is. Moreover, it did not cause or enhance VEGF R I-related side effects. The efficacy and safety of aPlGF, its pleiotropic and complementary mechanism to VEGF INTRODUCTION Antiangiogenic agents prolong the survival of cancer patients, however, without cure and at the expense of side effects (Hurwitz et al., 2004; Kramer and Lipp, 2007) . The role of VEGF and VEGFR-2 in tumor growth is well established, but other angiogenic factors switch on during cancer progression and induce resistance to VEGF R I monotherapy. By reducing tumor angiogenesis and increasing hypoxia, VEGF R Is rescue angiogenesis via other angiogenic factors. Combination therapy of antiangiogenic agents with complementary mechanisms could reduce resistance but might increase toxicity. PlGF is a pleiotropic cytokine that stimulates endothelial cell (EC) growth, migration, and survival; chemoattracts angiocompetent macrophages and bone marrow progenitors; and determines the metastatic niche. Unlike VEGF, PlGF selectively binds VEGFR-1 and its coreceptors neuropilin-1 and -2. Besides indirect effects (Park et al., 1994) , PlGF signals directly via VEGFR-1, thus, acting independently of VEGF in ECs, macrophages, bone marrow progenitors, and tumor cells, which primarily express VEGFR-1 (Clauss et al., 1996; Hattori et al., 2002; Kaplan et al., 2005) .
PlGF stimulates angiogenesis, leukocyte infiltration, tumor growth and stromal cell migration (Luttun et al., 2002a; Marcellini et al., 2006; Roy et al., 2005) , and revascularization of ischemic tissues (Luttun et al., 2002b) , indicating that PlGF has biological activity in vivo. An anti-PlGF antiserum inhibits tumor cell invasion in vitro (Taylor and Goldenberg, 2007) and vascular leakage in vivo (Carmeliet et al., 2001) , while PlGF overexpressing tumors grow less in VEGFR-1/TK À/À mice (Hiratsuka et al., 2001) . However, genetic studies show that PlGF is redundant for vascular development and maintenance, but contributes to the angiogenic switch in disease (Carmeliet et al., 2001; Rakic et al., 2003) . This raised the question whether PlGF inhibitors might reduce pathological angiogenesis but, unlike VEGF R Is, without affecting healthy blood vessels, and thus provide an attractive drug with a better safety profile. PlGF levels in plasma and tumors correlate with tumor stage, vascularity, recurrence, metastasis, and survival in various tumors Ho et al., 2007; Matsumoto et al., 2003; Parr et al., 2005; Wei et al., 2005) . Notably, PlGF is upregulated in cancer patients treated with VEGF R I therapy (Motzer et al., 2006; Rosen et al., 2007; Willett et al., 2005) , as well as in human tumors after radio-immunotherapy (Taylor et al., 2003) , suggesting a key role of PlGF in the angiogenic rescue. Here, we generated a neutralizing aPlGF and evaluated its therapeutic potential and mechanism of action in the inhibition of solid tumor growth.
RESULTS

Characterization of an Anti-PlGF Antibody
We developed a neutralizing murine anti-PlGF monoclonal antibody (clone 5D11D4; referred to as aPlGF) that specifically recognizes mouse PlGF-2 (all mouse proteins denoted without prefix; human proteins are preceded with ''h'') with a high affinity (K D = 7.0 3 10 À10 M). aPlGF inhibited the binding of PlGF to VEGFR-1 (IC 50 : 27 pM) and neuropilin-1, tyrosine phosphorylation of VEGFR-1 in response to PlGF, and the response of endothelial and tumor cells to PlGF, without, however, inhibiting the binding or activity of VEGF or other related factors ( Figures  1A-1D ; Figures S1A-S1F in the Supplemental Data available with this article online).
Effect of aPlGF on Tumor Growth and Metastasis
PlGF was undetectable in most healthy tissues but induced by hypoxia, abundant in all tumors analyzed and expressed by both tumor and stromal cells (Figures S1G and S1H; data not shown). When injecting B16 melanoma cells subcutaneously or pancreatic Panc02 tumor cells orthotopically, aPlGF dose-dependently inhibited tumor growth (Figures 2A-2D ) and reduced the incidence of local tumor invasion, bile duct stenosis and hemorrhagic ascites (n = 65-71; Table S1 ; for pharmacokinetics and rationale of dosing, see Note S1). aPlGF dose-dependently inhibited metastasis of Panc02 tumors to regional and distant lymph nodes, independent of primary tumor size (Figures 2E-2G ; Note S2). Metastasis to lymph nodes occurred in >78% of control mice, while only in 29% of aPlGF-treated mice (n = 18; p < 0.05; Table S1 ). Overall, aPlGF inhibited the growth and/or metastasis of 12 different tumor models tested, mostly by 55% to 66% (Figures 2H and 2I; Table S2 ), including human xenograft tumors (data not shown). aPlGF also suppressed the growth of established B16 tumors (by 35%) and the lodging of intravenously injected B16 tumor cells (by 50%; data not shown).
To evaluate how efficiently aPlGF inhibited tumor growth as compared to established VEGF R Is, we used an anti-VEGFR-2 antibody (aVEGFR-2). Compared to aVEGFR-2, aPlGF comparably inhibited the growth of B16 tumors ( Figure 2J ) or was less effective in inhibiting growth of Panc02 tumors, a VEGF R I-sensitive model (by 62 ± 3% versus 82 ± 2%; n = 45; p < 0.05). Interestingly, however, aPlGF was more effective in suppressing growth of CT26 tumors, a model relatively resistant to VEGF R Is (by 56 ± 3% versus 31 ± 4%; n = 90; p < 0.05; see also Figure 3D ). Similar results were obtained when using other aPlGF Enhances the Efficacy of Chemotherapy Exposure of Panc02 and B16 tumor cells to the cytostatic agents gemcitabine and cyclophosphamide dose-dependently increased PlGF expression ( Figure 3A ; Figure S2A ), providing a rationale to test whether aPlGF would enhance chemotherapy. Compared to monotherapy, combination therapy with aPlGF and gemcitabine inhibited Panc02 tumor growth more ( Figure 3B ). In the B16 model, aPlGF plus cyclophosphamide near completely inhibited tumor growth as compared to only the partial inhibition of tumor growth by either monotherapy alone ( Figure S2B ). Thus, aPlGF enhanced the tumor growth inhibitory effect of cytostatic agents.
aPlGF Enhances the Anticancer Activity of aVEGFR-2 VEGF R blockade increases plasma PlGF levels in cancer patients (Motzer et al., 2006; Rosen et al., 2007; Willett et al., 2005) . Plasma PlGF levels were undetectable in healthy mice, but elevated to $100 pg/ml in tumor-bearing mice ( Figure 3C ). Treatment of tumor-bearing mice with aVEGFR-2 elevated PlGF levels in the plasma ( Figure 3C ) and tumors (Note S3A). Plasma VEGF levels were also increased when tumor-bearing mice were treated with aVEGFR-2 ( Figure S2C ), but not by aPlGF (data not shown). ELISA confirmed that tumoral VEGF levels were upregulated in tumors by aVEGFR-2, but not by aPlGF (Note S3B).
The finding that PlGF levels were upregulated by aVEGFR-2 in tumor-bearing mice prompted us to examine whether aPlGF enhanced the antitumor effect of aVEGFR-2, using the colon CT26 tumor model, as it is relatively resistant to aVEGFR-2 (see above). Compared to the partial inhibition of tumor growth by monotherapy with aVEGFR-2 or aPlGF, their combination inhibited tumor growth more completely ( Figure 3D ), indicating that aPlGF enhanced the antitumor activity of aVEGFR-2.
We also examined whether aPlGF might substitute for aVEGFR-2. A maximal dose of aPlGF and aVEGFR-2 reduced tumor growth in Panc02 tumors by $56% and $83%, respectively ( Figure 3E) . A low dose of aVEGFR-2 (from here on defined as 5 mg/kg; three times per week) inhibited tumor growth by $30%, but when combined with aPlGF, tumor growth was reduced by $83%, i.e., to the same extent as monotherapy with a high dose of aVEGFR-2 ( Figure 3E ). Similar results were obtained when analyzing lymphatic metastasis of Panc02 tumor cells, whereby substitution of most of aVEGFR-2 by aPlGF yielded even more complete suppression than aVEGFR-2 monotherapy alone ( Figure 3F ). Thus, substitution of aVEGFR-2 with aPlGF resulted in a comparable or even greater antitumor/metastasis effect.
aPlGF Inhibits Tumor Angiogenesis aPlGF reduced tumor angiogenesis by $50% in all tumors analyzed, i.e., comparably or slightly less than aVEGFR-2 ( Figure 4A ; Figures S3A-S3F; Table S3 ). Double staining for CD31 and caspase-3 revealed that aPlGF induced EC apoptosis, indicating that aPlGF induced pruning of preexisting tumor vessels ( Figures 4B-4D ). In Panc02 tumors, a combination of aPlGF with a low dose aVEGFR-2 reduced tumor angiogenesis to the same extent as a high dose of aVEGFR-2 ( Figure 4A ). Also, in CT26 tumors, the combination of aPlGF plus aVEGFR-2 yielded the greatest inhibition of tumor angiogenesis ( Figure S3G ). Thus, aPlGF reduces tumor growth, at least in part, by inhibiting tumor angiogenesis. Similar to aVEGFR-2, aPlGF primarily reduced EC numbers, without affecting SMC counts, suggesting possible improvement of tumor vessel maturation ( Figures 4E-4H ).
aPlGF Inhibits Intratumoral Macrophage Recruitment VEGFR-1 + macrophages promote tumor growth and angiogenesis. aPlGF reduced F4/80 + macrophage infiltration, maximally by 74%, in both VEGF R I-sensitive (Panc02; Figure 4I ) and VEGF R I-resistant (CT26; Figures S4A, S4B, and S4E) tumors (Table S3) . It also normalized circulating monocyte counts in these tumor models ( Figure 4J ; Table  S3 ). In contrast, aVEGFR-2 failed to inhibit the macrophage infiltration and even slightly increased circulating monocyte counts (Figures 4I and 4J; Figures S4C and S4E) . Interestingly, the combination of aPlGF plus aVEGFR-2 inhibited macrophage infiltration and normalized tumorinduced monocytosis (Figures 4I and 4J; Figures S4D and S4E) , indicating that aPlGF predominated over aVEGFR-2. Thus, aPlGF and aVEGFR-2 substantially differ in their mechanism of regulating tumor inflammation. Similar findings were obtained when using a VEGF inhibitor (see below).
PlGF-Dependent Macrophage Recruitment
Confers Resistance to aVEGFR-2 CT26 tumors produced comparable amounts of VEGF and PlGF (data not shown), yet aVEGFR-2 inhibited their growth much less than aPlGF (see above). Since both antibodies comparably inhibited angiogenesis, the resistance of CT26 tumors to aVEGFR-2 could not be explained by its antiangiogenic activity alone. As aPlGF, but not aVEGFR-2, inhibited macrophage infiltration, we assessed whether the tumor responsiveness to aVEGFR-2 was dependent on tumor inflammation. We therefore used clodronate liposomes (referred to as clodrolip) to deplete macrophages (Zeisberger et al., 2006) . Clodrolip slowed down tumor growth in control mice but did not enhance the effect of aPlGF ( Figure 5A ). aPlGF alone was equipotent in inhibiting intratumoral macrophage infiltration, and clodrolip only slightly amplified the anti-inflammatory effect of aPlGF ( Figure 5B ). Tumor angiogenesis was reduced by clodrolip, indicating that macrophages were proangiogenic ( Figure 5C ). However, clodrolip did not further amplify the antiangiogenic effect of aPlGF, suggesting that aPlGF alone already efficiently depleted growing tumors from proangiogenic macrophages ( Figure 5C ). The finding that aPlGF inhibited tumor growth and angiogenesis more than clodrolip, while comparably inhibiting intratumoral macrophage infiltration, suggests that aPlGF inhibits tumor growth not only via an anti-inflammatory activity, but also via its antiangiogenic activity. Similar results were observed in orthotopic Panc02 tumors ( Figures S4F-S4H ).
In contrast, the combination of aVEGFR-2 and clodrolip was more effective in inhibiting tumor growth, indicating that depletion of mononuclear cells by clodrolip sensitized CT26 tumors to the inhibitory effect of aVEGFR-2 (Figure 5D ). Since aVEGFR-2 inhibited tumor angiogenesis without affecting tumor macrophage infiltration and clodrolip amplified the antiangiogenic activity of aVEGFR-2 2 (5 mg/kg) with aPlGF (50 mg/kg) inhibits angiogenesis comparably as 40 mg/kg aVEGFR-2 (n = 6; p = NS) and more efficiently than either aPlGF or 5 mg/kg aVEGFR-2 (n = 6; # p < 0.05).
(B and C) Double staining using anti-CD31 (green) and anti-caspase-3 (red) antibodies on orthotopic Panc02 tumors treated with control IgG 1 (B) and aPlGF (C). Arrowhead indicates apoptotic EC. (D) Bar graph represents percent of apoptotic EC area/total EC area (n = 8).
(E-H) Double staining for CD31 (green) and SMA (red) on Panc02 tumor sections after treatment with control IgG 1 (E), aPlGF (F) and aVEGFR-2 (G), and quantification of CD31 + and SMA + area/tumor area (H). Both aPlGF and aVEGFR-2 decrease CD31 + areas without affecting SMA + areas (n = 6).
Scale bar is 100 mm.
(I and J) aPlGF, but not aVEGFR-2, inhibits intratumoral macrophage recruitment (n = 10) (I) and abrogates Panc02 tumor-induced blood monocytosis (n = 6; x p < 0.05 versus nontumor-bearing mice) (J). aPlGF predominates over aVEGFR-2 treatment (n = 6-10). ( Figures 5E and 5F ), the infiltration of proangiogenic macrophages contributed to the resistance of CT26 tumors to aVEGFR-2. Thus, aPlGF and aVEGFR-2 act via distinct mechanisms: by blocking both tumor angiogenesis and inflammation, aPlGF inhibits growth of a VEGF R I-resistant tumor; in contrast, the antiangiogenic activity of aVEGFR-2 is unable to suppress growth of this VEGF R I-resistant tumor, since it fails to inhibit infiltration of proangiogenic macrophages.
aPlGF Inhibits Tumor Lymphangiogenesis To explain how aPlGF inhibited lymphatic metastasis of orthotopic Panc02 tumors, we analyzed lymphangiogenesis. aPlGF reduced LYVE-1 + peritumoral lymphatic vessel density and area by 75% and 87%, respectively (Figures 5G-5I; Figure S3H ). Consistent with previous findings that VEGF stimulates lymphangiogenesis, aVEGFR-2 also inhibited lymphangiogenesis in Panc02 tumors (Figure 5I) . Notably, combination of a low dose of aVEGFR-2 plus aPlGF resulted in a significantly greater inhibition of lymphangiogenesis than single treatments ( Figure 5I ). Thus, both aPlGF and aVEGFR-2 suppressed peritumoral lymphangiogenesis and amplified each other's antilymphangiogenic activity. Since lymphatic endothelial cells do not express VEGFR-1, we studied if aPlGF inhibited lymphangiogenesis indirectly. Indeed, aPlGF decreased Vegf-C levels, lymphangiogenesis, and lymph node metastasis comparably as clodrolip, suggesting that aPlGF inhibited the recruitment of prolymphangiogenic macrophages ( Figures 5J-5L ).
Negligible Induction of a Rescue Angiogenic Program by aPlGF
Resistance to antiangiogenic agents is, at least in part, determined by the induction of a compensatory angiogenic program. We therefore analyzed the tumor expression of several angiogenic genes. Treatment of VEGF R I-sensitive and -resistant tumor-bearing mice with aVEGFR-2, but not aPlGF, upregulated proangiogenic genes such as Sdf-1, Vegf, Plgf, Mmp9 , and Cxcl1 ( Figure 6A ). This upregulation was specific, as other genes involved in angiogenesis, such as Csf, Ccl-2, Egf, and Vegfr-3, were not upregulated (data not shown). Tumor hypoxia, resulting from the antiangiogenic treatment, may underlie the induction of such an angiogenic rescue program. We therefore assessed tumor hypoxia by staining for the hypoxia-marker pimonidazole (PIMO; Figures 6B-6D ). In orthotopic Panc02 tumors, aVEGFR-2 (but not aPlGF) significantly increased the PIMO + fraction of the tumor ( Figure 6E ). Further, aVEGFR-2 reduced the vessel area more than aPlGF (lumen/tumor area: 4.6 ± 0.4% in controls versus 3.3 ± 0.4% after aPlGF and 1.2 ± 0.2% after aVEGFR-2; n = 5; p = 0.04 versus aPlGF; p < 0.0001 versus aVEGFR-2). In addition, aVEGR-2, but not aPlGF, reduced in vivo tumor perfusion (tumor/kidney perfusion: 48 ± 10% in controls versus 17 ± 3% after aVEGFR-2, n = 14; p < 0.01; and 45 ± 9% after aPlGF, n = 14; p = NS). Similarly, in CT26 tumors, aVEGFR-2 caused more tumor cell hypoxia than aPlGF, resulting in larger necrotic tumor areas ( Figures S4I and S4J) . Thus, compared to aVEGFR-2, aPlGF caused less severe intratumoral hypoxia, which may explain the minimal rescue angiogenic program.
aPlGF Enhances VEGF-Trap Therapy To assess whether aPlGF mechanistically also differs from a specific VEGF inhibitor, we used a soluble form of VEGFR-2 (sFlk1) that ''traps'' VEGF selectively (i.e., thus, not PlGF or VEGF-B). Upon hydroporation, circulating sFlk1 was elevated during the entire experiment to levels (2,900 ± 790 ng/ml), previously reported to inhibit tumor growth (Davidoff et al., 2002) . sFlk1 inhibited orthotopic Panc02 tumor growth, angiogenesis, and lymph node metastasis (Figures 6F and 6G ; Table S4 ) with plasma sFlk1 levels correlating with tumor growth inhibition (data not shown). The combination of aPlGF with sFlk1 was more efficient in inhibiting tumor growth and lymphatic metastasis than each treatment alone ( Figures 6F and 6G ). When using VEGF R I-resistant CT26 tumors, sFlk1 inhibited tumor growth only insignificantly by 20% ( Figure 6H ) without any correlation between sFlk1 levels and tumor inhibition, confirming that this tumor is resistant to VEGF R I therapy. Similar to aVEGFR-2, sFlk1 inhibited tumor angiogenesis but failed to inhibit intratumoral macrophage recruitment (Table S4) , while clodrolip rendered this tumor again sensitive to sFlk1 ( Figure 6I ). Thus, even despite its antiangiogenic activity, sFlk1, like aVEGFR-2, is unable to inhibit macrophage recruitment and, hence, CT26 tumor growth. aPlGF, by contrast, differs from these VEGF R Is by inhibiting angiogenesis and macrophage infiltration and, thereby, growth of this VEGF R I-resistant tumor. Unlike aPlGF, sFlk1 also switched on an angiogenic rescue program, including Vegf, Plgf, and Fgf-2 (data not shown).
Safety Profile of the aPlGF Antibody
Treatment with VEGF R Is causes thrombosis, hypertension, microvascular pruning in healthy organs, interruption of pregnancy, and other side effects (Hurwitz et al., 2004; Kamba et al., 2006; Kramer and Lipp, 2007) . However, treatment of healthy mice with aPlGF did not affect body weight, did not cause any obvious organ pathology upon inspection and histological analysis, did not alter the clinical chemistry or hematological blood profile, and did not increase proteinuria (data not shown). When analyzing the morphology of quiescent vessels in different healthy organs, treatment with aVEGFR-2, but not aPlGF, for 3 weeks reduced the number of capillary branching points/ mm 2 in the trachea by 34 ± 2% ( Figures 7A-7C ) and capillary profiles/mm of follicle perimeter in the thyroid gland by 21 ± 1% (n = 14; p < 0.05; Table S5 ). Moreover, the combination of aPlGF and aVEGFR-2 did not aggravate the adverse effect of aVEGFR-2 on vessel pruning ( Figure 7D ). Thus, aPlGF enhanced the antitumor growth efficacy of aVEGFR-2 without, however, aggravating its toxicity. We also measured the circulating levels of plasminogen activator inhibitor-1 (PAI-1), a fibrinolytic inhibitor of clot lysis, released by stressed ECs and known risk factor of thrombosis. Treatment with aVEGFR-2, but not aPlGF, caused a 2.7-fold increase of PAI-1 levels (n = 5; p < 0.05; Figure 7E ). Furthermore, after 3 weeks of treatment, the mean blood pressure was elevated in mice given aVEGFR-2 (73 ± 3.2 mmHg after IgG 1 versus 95 ± 3.9 mmHg after aVEGFR-2; n = 9; p < 0.002), but not aPlGF (74 ± 5.3 mmHg after IgG 1 versus 74 ± 3.9 mmHg after aPlGF; n = 9; p = NS). The relative teratogenicity of aPlGF and aVEGFR-2 was analyzed in pregnant mice from the (E) aPlGF does not upregulate plasma PAI-1 levels in healthy mice (n = 5). White and gray bars represent murine and rat IgG 1 , respectively.
(F) Mice were treated with aPlGF, aVEGFR-2, or control IgG 1 throughout pregnancy, and body weight was monitored. aVEGFR-2, but not aPlGF, arrests pregnancy and embryonic development from day E7 onward (n = 10).
(G and H) Upon resection at day E8, the uteri of mice treated with aVEGFR-2 contained dead early stage embryos (n = 10) (G), whereas aPlGF did not impair embryonic development (n = 10) (H). *p < 0.05 versus control. Error bars represent mean ± SEM.
day of plug-check throughout pregnancy. Mice treated with aVEGFR-2 failed to gain weight beyond day 6, suggesting that embryonic development was arrested (Figure 7F) . At day 8 of pregnancy, their uteri contained dead, partially resorbed early-stage embryos and a pale placenta, indicating that aVEGFR-2 inhibited placental vascular development ( Figures 7G and 7H ). In contrast, aPlGF did not interrupt the pregnancy-associated weight gain, nor did it abort embryonic development, and resulted in normal litters and healthy pups, that grew up normally (Table S5) . In contrast to aVEGFR-2, aPlGF did also not aggravate the cardiotoxicity induced by doxorubicin (data not shown). sFlk1 and VEGFR tyrosine kinase inhibitors had a comparable toxicity profile to aVEGFR-2 (data not shown).
DISCUSSION
The primary findings of this study are (1) aPlGF monotherapy inhibits the growth and metastasis of >12 different tumor models; (2) cytotoxic drugs upregulate PlGF expression by tumor cells, and aPlGF amplifies the antitumor effect of chemotherapy; (3) aVEGFR-2 and sFlk1 therapy upregulate PlGF levels, and aPlGF enhances and partially substitutes aVEGFR-2 and sFlk1 monotherapy; (4) aPlGF mimics aVEGFR-2 and sFlk1 in inhibiting tumor angiogenesis but differs by inhibiting intratumoral macrophage infiltration and acts, thus, via complementary mechanisms to VEGF R Is; (5) unlike aVEGFR-2, aPlGF does not induce an angiogenic rescue/antiangiogenic escape program (which might lead to resistance against antiangiogenic therapy) because it inhibits macrophage infiltration and does not cause severe hypoxia; and (6) aPlGF is not associated with typical VEGF R I side effects but exhibits a superior safety profile. This study is the first to document the pharmacological properties of a specific PlGF-inhibitor (Note S5).
Mechanisms of aPlGF
The antitumor activity of aPlGF depends, in part, on its pleiotropic effects. First, PlGF stimulates EC growth and migration (Autiero et al., 2003; Carmeliet et al., 2001) , mobilizes angiocompetent bone marrow progenitors (Hattori et al., 2002; Kaplan et al., 2005) , and acts as a survival factor for existing vessels. Thus, aPlGF not only inhibits new vessel growth, but also causes regression of existing tumor vessels. Second, aPlGF impaired tumor lymphangiogenesis. Our finding that aPlGF augmented the antilymphangiogenic activity of aVEGFR-2 suggests that it acts via complementary VEGF-unrelated mechanisms. Indeed, consistent with the role of macrophages in pathological lymphangiogenesis (Cursiefen et al., 2004) , clodrolip inhibited lymphatic metastasis, lymphangiogenesis, and tumoral Vegf-C levels as effectively as aPlGF, indicating that the effect of aPlGF on lymphatic vessels is mainly mediated via macrophage inhibition. An inflammation-dependent role of PlGF in lymphangiogenesis might explain why PlGF À/À mice do not exhibit spontaneous lymphatic defects (Carmeliet et al., 2001 ).
Third, aPlGF is anti-inflammatory, consistent with the fact that PlGF chemoattracts VEGFR-1 + macrophages (Luttun et al., 2002a; Pipp et al., 2003) . Tumor-associated macrophages (TAMs) participate in angiogenesis by secreting angiogenic factors or indirectly by producing proteases that release sequestered angiogenic factors. An increase in TAMs is associated with tumor progression, metastasis, and poor prognosis, both in humans as well as in various implanted or spontaneously arising tumor models in mice (Pollard, 2004) . Thus, by inhibiting their recruitment, aPlGF also inhibits tumor growth. Whether aPlGF also blocks the role of macrophages in establishing the premetastatic niche, as suggested by genetic data using VEGFR-1/TK À/À mice (Hiratsuka et al., 2002) , remains to be established. Another mechanism of aPlGF may relate to its cytostatic activity for malignant cells (data not shown). The relative role of the antiangiogenic, antilymphangiogenic, anti-inflammatory, and cytostatic activity of aPlGF in spontaneously arising tumor models in transgenic mice is currently under investigation. Initial findings that loss of PlGF inhibits carcinogen-induced skin cancer growth promise to use such models to evaluate the activity of aPlGF. Our data also indicate that aPlGF, by inhibiting macrophage recruitment, enhances the responsiveness of tumors to VEGF R Is. Indeed, CT26 tumors are relatively resistant to aVEGFR-2 and sFlk1, but, following macrophage depletion, they became sensitive to these VEGF R Is. Thus, macrophages counteract VEGF R Is, presumably by releasing angiogenic factors other than VEGF. Since macrophages do not express VEGFR-2 (Clauss et al., 1996) , aVEGFR-2 failed to inhibit macrophage tumor infiltration. sFlk1 was also ineffective-this is perhaps more surprising, as VEGF also chemoattracts macrophages. However, aVEGFR-2 and sFlk1 also upregulated the expression of the macrophage chemoattractants PlGF, VEGF, FGF-2, and G-CSF, which might have counteracted VEGF R I treatment. Thus, by blocking macrophage infiltration, aPlGF not only reduced tumor growth, but also rendered tumors more responsive to VEGF R Is.
Enhancement of Chemotherapy and VEGF R
Inhibitor Therapy by aPlGF Like bevacizumab in patients (Hurwitz et al., 2004) , aPlGF amplified the effect of chemotherapy in preclinical mouse tumor models. This may, at least in part, be attributable to the fact that cytotoxic agents upregulate PlGF in tumor cells. Obviously, additional mechanisms might contribute. For instance, it remains to be determined whether the effects of aPlGF on tumor vessel perfusion will improve the delivery of cytotoxic drugs, or whether aPlGF might also inhibit EPC mobilization in response to chemotherapy. Treatment with a single antiangiogenic agent may lead to acquired drug resistance based on an escape mechanism via induction of an angiogenic rescue program; for instance, FGF is upregulated after aVEGFR-2 treatment (Casanovas et al., 2005) . Plasma PlGF levels are upregulated 3-to >10-fold in colorectal cancer patients treated with bevacizumab (Willett et al., 2005) , as well as in renal cell cancer patients treated with Sunitinib (Motzer et al., 2006) . Induction of PlGF expression has also been proposed to contribute to human xenografted tumor recurrence after immunoradiation therapy (Taylor et al., 2003) . Furthermore, PlGF expression correlates with the tumor stage, vascularity, metastasis, recurrence, and survival in different malignancies. In this study, aVEGFR-2 and sFlk1 upregulated plasma PlGF levels in tumor-bearing mice, mimicking the effect of VEGF R Is in clinical trials. Combination treatment of aPlGF with aVEGFR-2 and sFlk1 resulted in more sustained tumor growth inhibition than monotherapy with each agent alone. Thus, not only the upregulation of PlGF by VEGF R Is, but also the pleiotropic and complementary mechanisms of aPlGF relative to VEGF or VEGFR-2 selective inhibitors, suggest that aPlGF may be useful for monotherapy, as well as an adjunct to VEGF R Is.
Resistance to aPlGF? An important question is how to avoid/minimize resistance to antiangiogenic agents. Antiangiogenesis is expected to prune the tumor vasculature, thereby depriving tumor cells from oxygen and causing tumor necrosis. The resultant hypoxia is, however, a strong stimulus for the expression of angiogenic cytokines, which induce an angiogenic rescue program that could evoke resistance to VEGF R Is (Sweeney et al., 2003) . Our studies show that hypoxia upregulated PlGF release from tumor cells and that aVEGFR-2 not only inhibited tumor angiogenesis but also increased tumor hypoxia and upregulated the production of PlGF and other angiogenic molecules such as FGF-1, FGF-2, SDF-1, CXCL1, and MMP-9. Each of these cytokines can be produced by tumor cells, macrophages, and other stromal cells and are hypoxia-inducible (Casanovas et al., 2005; Semenza, 2003) . sFlk1 induced a similar angiogenic rescue program (data not shown). In contrast, aPlGF did not switch on such an angiogenic rescue program. Indeed, though aPlGF reduced tumor vessel density, it did not cause as severe hypoxia and necrosis as aVEGFR-2, suggesting that the residual vasculature permitted a critical threshold of oxygenation. The larger vascular perfusion area and preserved perfusion in the residual tumors after aPlGF as compared to aVEGFR-2 are consistent with such model. Besides the lower hypoxia, the inhibition of intratumoral macrophage infiltration may also explain the lack of upregulation of these angiogenic factors in aPlGF-treated tumors. Also, aPlGF overruled the effect of aVEGFR-2 on tumor macrophage infiltration and, coincidentally, on the upregulation of VEGF by aVEGFR-2 (although aVEGFR-2 upregulated tumor VEGF levels, aPlGF/aVEGFR-2 combination normalized VEGF levels again; data not shown). Thus, aPlGF enhances the antitumor efficacy of aVEGFR-2, yet it does not increase, but might even decrease, the resistance to aVEGFR-2.
Safety and Therapeutic Profile of aPlGF
The safety of antiangiogenic agents will be a determining factor for their wider spread use in particular oncological indications (children, pregnant women, and patients at risk for developing VEGF R I-related side affects) and beyond oncology. Side effects of VEGF R Is include teratogenicity, pruning of healthy vessels, thrombosis, hypertension, and other effects. Fetal development depends on the formation of a vascularized placenta-VEGF is essential for this process (Carmeliet et al., 1996; Ferrara et al., 1996) . Not surprisingly, therefore, VEGF R Is interrupted pregnancy by inhibiting angiogenesis in the placenta. In contrast, aPlGF did not affect fetal development consistent with genetic data that embryos develop normally in the absence of PlGF (Carmeliet et al., 2001) . VEGF R Is do, however, also cause pruning of quiescent vessels in healthy tissues because they require VEGF survival signals for their maintenance. aPlGF did not prune such quiescent vessels, presumably not only because these fenestrated ECs lack VEGFR-1 (Kamba et al., 2006) , but also because expression of PlGF (unlike VEGF) is negligible in quiescent tissues in baseline conditions (data not shown). In addition, aPlGF did not aggravate vessel pruning induced by aVEGFR-2, while the combination more effectively inhibited tumor angiogenesis and growth. Data that a VEGF-trap (capturing VEGF, VEGF-B, and PlGF) did not aggravate the neonatal vascular defects induced by an anti-VEGF antibody are consistent with our findings (Malik et al., 2006) . Some of the toxicity of the VEGF R Is has been ascribed to the deprivation of quiescent ECs from critical VEGFdependent survival and maintenance signals, thereby inducing EC dysfunction, leading to a hypertensive and prothrombotic state. Indeed, VEGF upregulates the vasodilating nitric oxide and maintains the endothelium in an antithrombotic state by upregulating tPA and downregulating PAI-1 (Carmeliet et al., 1997) . In contrast, PlGF is only a survival signal for growing ECs, but not for quiescent vessels (as suggested by the PlGF knockout phenotype), and is not detectable in healthy vessels. Whatever the mechanisms, the safety of aPlGF is striking and medically relevant.
Because of the excellent safety profile, aPlGF could be combined with VEGF R Is to increase efficacy without increased toxicity or resistance. Besides, single aPlGF therapy may also offer novel opportunities for the treatment of pathological conditions, for which the adverse effects of VEGF R Is may be excessive and prohibitive, such as cancer in children and young (pregnant) women, or perhaps in patients at risk for thrombotic, cardiac, or other complications. Our data also warrant further analysis of systemic aPlGF treatment for ocular neovascularization as an alternative to intraocular administration of antiangiogenic agents.
EXPERIMENTAL PROCEDURES
Generation and Characterization of aPlGF aPlGF was selected and produced using in vitro hybridoma cell culture technologies developed at ThromboGenics NV. aPlGF was purified from cell culture supernatant by affinity chromatography on ProSep vA Ultra (Millipore). Affinities of aPlGF were determined by using Biacore assays. Competitive inhibition studies were performed by ELISA on immobilized soluble receptors using biotinylated growth-factorspecific antibodies (all R&D Systems) and on hVEGFR-1 overexpressing cells using 125 I-radiolabeled ligand. aPlGF was used at submolar to 1000-fold molar excess. For FRET analysis, porcine aortic endothelial (PAE) cells transfected with two plasmids expressing Npn1 fused to the cyan (ECFP) and the yellow (EYFP) variants of GFP were used. For VEGFR-1 tyrosine phosphorylation studies, 293T cells overexpressing VEGFR-1 were used (Errico et al., 2004) .
Pharmacokinetics
Mice were i.p. injected with cold or 125 I-radiolabeled aPlGF or aVEGFR-2. Antibody plasma levels up to 21 days were determined by ELISA or by counting total and TCA-precipitable radioactivity using a gamma counter.
In Vitro Migration Assay Subconfluent cell monolayers were grown in serum-free medium containing microchemotaxis chambers, of which the bottom wells were filled with diluted chemoattractants. After incubation at 37 C for 10 hr, filters were Giemsa stained and cells were counted. sFlk1 Hydroporation 40 mg/mouse of a vector encoding sFlk1 or a control vector (Davidoff et al., 2002) were suspended in 2.5 ml of Ringer's solution and injected into the tail vein. sFlk1 plasma protein levels were determined using a sVEGFR-2 immunoassay (R&D Systems).
Macrophage Depletion
Clodronate encapsulated liposomes (clodrolip) were administered i.p. 24 hr after tumor cell implantation (100 mg/kg); repeated injections (50 mg/kg) every fourth day prevented macrophage repopulation (Zeisberger et al., 2006) .
ELISA
Concentrations of PlGF, VEGF, and VEGF/PlGF heterodimers were quantified using PlGF and VEGF immunoassays (R&D Systems).
Values from cell culture media were normalized to end-stage cell count (pg/10 6 cells). Similar data were obtained when correcting the data for protein content.
Histology and Morphometric Analyses
All methods for histology and immunostaining on paraffin and cryosections have been described (Carmeliet et al., 1996; Luttun et al., 2002b) . The following primary antibodies were used: rat anti-CD31, rat anti-F4/ 80/Mac1, rat anti-CD45 (all Becton Dickinson), rabbit anti-LYVE-1 (Cell Signaling), mouse anti-SMCa actin (Sigma), and rat anti-caspase-3 (Abcam). Signals were detected using fluorescently conjugated secondary antibodies (Alexa 488 or 546, Molecular Probes) or peroxidase-labeled IgGs (Dako) followed by tyramide signal amplification (Perkin Elmer, Life Sciences). (Lymph)-angiogenesis and tumor inflammation were assessed by quantification of CD31 + and LYVE-1 + microvascular density, or CD31 + , LYVE-1 + , and F4/80 + area/total tumor area using a Zeiss Axioplan microscope with KS300 image analysis software.
qRT-PCR Quantitative RT-PCR was performed as described (Carmeliet et al., 2001; Luttun et al., 2002b) using the probes and primers listed in Table S6 .
Hypoxia Assesment and Tumor Perfusion
Tumor hypoxia was detected 2 hr after injection of 60 mg/kg pimonidazole hydrochloride into tumor-bearing mice. To detect the formation of pimonidazole adducts, tumor sections were immunostained with hypoxyprobe-1-Mab1 (Chemicon) following the manufacturer's instructions. Tumor perfusion was analyzed using fluorescent microspheres (Luttun et al., 2002b) .
Assessment of the Safety Profile of aPlGF Female Swiss mice were treated with aPlGF, aVEGFR-2, control IgG 1 , or sFlk1 for 3 weeks. Tracheal vessel patency was assessed by in vivo injection of FITC-labeled Lycopersicon esculentum lectin. Tracheas were removed, immersed in fixative for 1 hr and processed as whole mounts for immunohistochemistry (Kamba et al., 2006) . Capillary branching points per unit area overlying the cartilage rings were counted. Vascular density in paraffin sections of thyroid was expressed as a number of capillary profiles per millimeter of follicle perimeter. PAI-1 plasma levels were determined by ELISA (Declerck et al., 1995) , and blood pressure was assessed by intraluminal hemodynamic measurements.
Statistics
Data represent mean ± SEM of representative experiments unless otherwise stated. Statistical significance was calculated by Student's t test or ANOVA where indicated (Prism v4.0b), considering p < 0.05 as statistically significant. IC 50 was calculated using WinNonlin v5.1.
Supplemental Data
The Supplemental Data include five supplemental notes, four supplemental figures, six supplemental tables, and Supplemental Experimental Procedures, and can be found with this article online at http://www.cell.com/cgi/content/full/131/3/463/DC1/.
